Aclaris Therapeutics (ACRS) Current Leases (2017 - 2023)

Aclaris Therapeutics' Current Leases history runs 5 years deep, the most recent figure standing at $426000.0 for Q4 2023.

• On a quarterly basis, Current Leases fell 37.72% year-over-year to $426000.0 in Q4 2023; TTM through Dec 2023 was $426000.0, a 37.72% decrease from a year earlier, with the FY2023 full-year figure at $426000.0, down 37.72% from the prior year.
• Current Leases climbed to $426000.0 in Q4 2023 per ACRS's latest filing, from $310000.0 in the prior quarter.
• Across five years, Current Leases topped out at $766000.0 in Q3 2022 and bottomed at $310000.0 in Q3 2023.
• The 3-year median for Current Leases is $643500.0 (2022), against an average of $585125.0.
• Across the five-year window, Current Leases dropped 1.3% in 2022 and slumped 59.53% in 2023, its largest moves.
• Year by year, Current Leases stood at $693000.0 in 2021, then fell by 1.3% to $684000.0 in 2022, then sank by 37.72% to $426000.0 in 2023.
• Per Business Quant, the three latest ACRS Current Leases figures stand at $426000.0 (Q4 2023), $310000.0 (Q3 2023), and $458000.0 (Q2 2023).